Home
Drug Discovery
21 March - 22 March 2018
Drug Discovery

SAE Media Group is proud to present its 2nd annual conference on Drug Discovery, taking place on 21st-22nd of March 2018 in Central London.
 

This conference will bring together key opinion leaders and senior industry experts to discuss the latest developments in drug discovery strategies. As the industry is experiencing radical changes in approaches to the discovery of new compounds, it is vital to look beyond to the next generation of enabling tools and technologies. This will assist rational, fast and successful drug discovery.


Drug Discovery 2018 provides an unprecedented opportunity to gain insight into the use of Artificial Intelligence in in silico drug discovery, as well as discussing 3D structure based-discovery, medicinal and discovery chemistry, translational medicine and the use of CRISPR cas-9 gene editing techniques and PROTAC's. 

 

VIP - To all the SAE Media Group delegates choosing to stay at the Copthorne Tara Hotel, we will offer an upgrade to a superior room and welcome drink voucher
 

FEATURED SPEAKERS

Alastair Lawson

Alastair Lawson

Head of Structural Biology and Research Fellow, UCB
Andrew Hopkins

Andrew Hopkins

Professor & Chief Executive Officer, University of Dundee & Exscientia
Christoph Dumelin

Christoph Dumelin

Laboratory Head, Novartis Institutes for BioMedical Research (NIBR), Novartis
Claus Bendtsen

Claus Bendtsen

Executive Director & Head of Quantitative Biology, AstraZeneca
Darren Green

Darren Green

Director of Molecular Design, GSK
Gary Allenby

Gary Allenby

Business Development Director and Chief Scientific Officer, Aurelia Bioscience
Gisbert  Schneider

Gisbert Schneider

Professor, Chair for Computer-Assisted Drug Design, ETH Zürich
Guido Hanauer

Guido Hanauer

Chief Executive Officer, GHPC GmbH
Hasane Ratni

Hasane Ratni

Expert Scientist, F. Hoffmann-La Roche Ltd.
John Harling

John Harling

Director of Chemistry for the Protein Degradation DPU, GSK
Patrick Jimonet

Patrick Jimonet

Director, External Innovation Drug Discovery, Sanofi
Ralph Minter

Ralph Minter

Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune
Reyk Horland

Reyk Horland

Vice President, Business Development, TissUse GmbH
Roderick  Hubbard

Roderick Hubbard

Professor & Senior Fellow, University of York & Vernalis Research
Stevan Djuric

Stevan Djuric

Vice President, Discovery Chemistry and Technology, AbbVie
Steve Rees

Steve Rees

Vice President Discovery Biology, Astra Zeneca
Susanne Muller-Knapp

Susanne Muller-Knapp

Senior Project Manager Chemical Probes, SGC Frankfurt, Goethe University Frankfurt
Ursula Egner

Ursula Egner

Director, Head of Structural Biology, Bayer AG
William Janzen

William Janzen

Executive Director, Lead Discovery, Epizyme

Alastair Lawson

Head of Structural Biology and Research Fellow, UCB
Alastair Lawson

Alastair is the Head of Structural Biology and a Research Fellow at UCB

Alastair studied for his Ph.D. at the Tenovus Research Laboratory at Southampton General Hospital, where he worked with Professor George Stevenson on patient-specific, antibody-based therapy for leukemia. He joined Celltech as a research scientist in 1983, and has been closely involved with the discovery of therapeutic antibodies, including Cimzia®, Evenity®, olokizumab, dapirolizumab pegol and bimekizumab, together with antibody-drug conjugates, Mylotarg® and Besponsa®.

Alastair led the development of UCB’s proprietary antibody discovery core platform, and currently heads UCB’s antibody-enabled small molecule drug discovery initiative, in which information from antibodies is applied to the discovery of new generations of small molecules addressing protein-protein interactions.
 

Andrew Hopkins

Professor & Chief Executive Officer, University of Dundee & Exscientia
Andrew Hopkins

Andrew Hopkins is the founder and CEO of Exscientia Ltd. Exscientia is the first company to automate drug design, using A.I., surpassing conventional human endeavors. Andrew is the author of some of the most highly cited papers in modern drug discovery. Prof Hopkins spent ten years at the Pfizer, following his DPhil at the University of Oxford. Subsequently, he was one of the youngest professors when he was appointed to a Chair at the University of Dundee. Prof Hopkins has raised around £50 million for commercial and academic research activities. He has won several awards for his work including the Royal Society of Chemistry’s Entrepreneur of the Year and the Capps Green Zomaya Medal, the BBSRC Commercial Innovator of the Year, Scottish Enterprise Life Science Entrepreneurial Leadership Award, and the Corwin Hansch Award. Andrew is a Fellow of the RSE, the RSC, the RSB and the LSW. Prof Hopkins lives in Oxford, UK.

Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.

Benjamin Taylor

Associate Principal Scientist, AstraZeneca
Benjamin Taylor

Christoph Dumelin

Laboratory Head, Novartis Institutes for BioMedical Research (NIBR), Novartis
Christoph Dumelin

Christoph E. Dumelin is a laboratory head at the Novartis Institutes of Biomedical Research in Basel, Switzerland, where he is applying different encoded library technologies to drug discovery projects. Before working at Novartis, he worked on DNA-encoded libraries at X-Chem Pharmaceuticals, Waltham, Massachusetts, USA, and on whole-blood pool contrast agents at Philochem, Zurich, Switzerland. He obtained his M.Sc. in biochemistry from the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, and his Ph.D. in pharmaceutical sciences at the ETH Zurich with Dario Neri. He completed his postdoctoral training in chemical biology with David Liu at Harvard University, Cambridge, USA.

Christoph Dumelin

Investigator III, Novartis Pharmaceuticals
Christoph Dumelin

Claus Bendtsen

Executive Director & Head of Quantitative Biology, AstraZeneca
Claus Bendtsen

Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, analytics, mathematical modeling, and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.

Darren Green

Director of Molecular Design, GSK
Darren Green

Darren Green is Director of Molecular Design, GlaxoSmithKline. Based at Stevenage, his group specialises in the application of molecular design, data analysis, predictive modelling and chemoinformatics methods to drug discovery. Darren also leads the Compound Collection Enhancement strategy for GSK.


Darren has a PhD in Theoretical Chemistry from the University of Manchester and is a Fellow of the Royal Society of Chemistry.
 

Gary Allenby

Business Development Director and Chief Scientific Officer, Aurelia Bioscience
Gary Allenby

Gary Allenby, Aurelia Bioscience

Biography:

After completing a Ph.D. in reproductive toxicology I post-doc’ed at Hoffmann La Roche U.S.A, studying the pharmacology of retinoid biology. I returned to the U.K. into Lead Generation at Glaxo Wellcome, developing cell-based assays and working with vendors to validate new technologies for screening. In 2000 I joined Hit Identification at AstraZeneca, developing assays for respiratory and inflammatory disease and continuing to work with vendors.

In 2011 I became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organisation specialising in the development of cell-based assays for compound and biologics screening. Our unique selling point is the development of more physiological phenotypic assays.
 

Gisbert Schneider

Professor, Chair for Computer-Assisted Drug Design, ETH Zürich
Gisbert  Schneider

Gisbert Schneider is a full professor at ETH Zurich, holding the Chair for Computer-Assisted Drug Design. He is recognized as being a pioneer in the integration of machine-learning methods into practical medicinal chemistry, and for his coining the phrases ‘scaffold-hopping’ and ‘frequent hitter’. His career has led him from the pharmaceuticals division at Roche to academia, initially to the Goethe-University in Frankfurt where he held the Beilstein Endowed Chair for Chem- and Bioinformatics, and then to his current position at ETH in Zurich. He is an elected Fellow of the University of Tokyo, and the recipient of the 2018 Herman Skolnik Award for his seminal contributions to de novo design of bioactive compounds. He has co-founded several start-up companies including inSili.com GmbH, AlloCyte Pharmaceuticals AG, and Endogena Therapeutics Inc.

Guido Hanauer

Chief Executive Officer, GHPC GmbH
Guido Hanauer

Hasane Ratni

Expert Scientist, F. Hoffmann-La Roche Ltd.
Hasane Ratni

Dr H. Ratni is currently an Expert Scientist, Medicinal Chemistry, at F. Hoffmann-La Roche Ltd., pRED, Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland.
 

He received his PhD at the University of Geneva and a post-doc at Tokyo before joining F. Hoffmann-La Roche Ltd in 2001. His research has mainly been devoted to the areas of neuroscience (for example neurokinin receptors, or V1a receptor antagonist now in human clinical trials, phase II, for autism). In 2005, he participated in a secondment within the Roche group at Chugai Pharmaceutical Co. Ltd, Gotemba Japan, in the field of renal disease. He was the chemistry discovery project leader of the SMN program aiming for a treatment for spinal muscular atrophy, now undergoing pivotal clinical trials in patients. His current focus is on gamma secretase modulator for Alzheimer disease.
 

He is an author or co-author of more than 100 patents and publications. In 2014 he received the Roche Leo Sternbach Award for Innovation in Chemistry and in 2016 the Gold medal at the Roche Patent Inventor’s recognition event.
 

John Harling

Director of Chemistry for the Protein Degradation DPU, GSK
John Harling

Mark Davies

Vice President, Biomedical Informatics, BenevolentAI
Mark Davies

Mark is the VP Biomedical Informatics at BenevolentAI. He has a background in molecular genetics, bioinformatics (BSc University of Sussex) and computer science (MSc Birkbeck College) and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Project and eventually moved on to building chemogenomics and druggability assessment systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI), as one of the founding members and technical lead for the ChEMBL database, the largest open-source Structure Activity Relationship (SAR) database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI.

Nicholas Clare

Technical Project Leader, Axol Bioscience Ltd
Nicholas Clare

Nicholas Clare, Field Application Scientist, Axol Bioscience Ltd.
Nick Clare has over 16 years’ experience in the life science industry and the drug discovery process. He has worked for global pharmaceutical and innovative biotechnology companies.
During his career he has been involved in R&D and production within the cell culture process, working with and developing cellular models from cell lines, primary cells and stem cells to automated processing. He was responsible for leading a team that produced iPSC banks as part of the European Bank of Induced Pluripotent stem cells (EBiSC).
Now as Technical Project Leader at Axol bioscience he oversees custom projects and technical resources.
 

Patrick Jimonet

Director, External Innovation Drug Discovery, Sanofi
Patrick Jimonet

Patrick Jimonet’s present role at Sanofi is to bring external innovation to the early portfolio and the Lead Generation process; his particular focus is on modalities, technologies and innovative biology through various and novel business models and partnerships.
Previous assignments were the identification of key areas for improvement in early phases of discovery, leadership of a global interdisciplinary team responsible for the identification of novel GPCR targets and validated tool compounds to enter the portfolio of therapeutic units, manager of multi-cultural teams of Ph.Ds with project leadership positions, project leader of projects from hit finding to clinical candidate.
All activities have been performed at Sanofi and predecessor companies in France and in the US. Patrick received his PhD in chemistry at the Institut de Chimie des Substances Naturelles of the CNRS in Gif-sur-Yvette, France.

Ralph Minter

Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune
Ralph Minter

Following a PhD in Immunology from the University of Durham in 1999, Ralph has been working in Antibody Discovery and Protein Engineering (ADPE) at MedImmune, developing candidate therapies in the areas of oncology, autoimmune disease, asthma and infection. Several of these candidate drug molecules are now progressing through clinical trials (including the antibody Benlysta®, approved in 2011 for SLE). As Director, Fellow at MedImmune, Ralph actively pursues novel scientific and collaborative opportunities within the biologics field and has published 31 papers to date, covering diverse areas such as phenotypic drug discovery, antibody and protein engineering and novel target biology. His current focus is on the delivery of biological macromolecules into cells.

Reyk Horland

Vice President, Business Development, TissUse GmbH
Reyk Horland

Since 2010 Reyk is actively involved in the development of TissUse’s Multi-Organ-Chip platform for culture analysis of drug candidates, cosmetics, chemicals and consumer products. He currently holds the position of Head of Business Development at TissUse. Prior to TissUse Reyk studied Biotechnology at the Technische Universität Berlin and specialized in Medical Biotechnology. During his academic career, he was involved in various tissue-engineering programs, all with a focus on bringing the respective products to market.

Roderick Hubbard

Professor & Senior Fellow, University of York & Vernalis Research
Roderick  Hubbard

Professor Rod Hubbard has been an academic at York for over 35 years working with methods for analysis and exploitation of protein structure. He developed molecular graphics and modelling methods in the 1980s and helped build Structural Biology at York during the 1980s and 1990s. He worked on the structure of many proteins of therapeutic importance combined with studies of protein-ligand interactions and methods in structure-based design. In 1997, he was a founding SAB member of what became Vernalis. Since 2001 he has split his time between Vernalis (fragment and structure based drug discovery) and York (fragment methods for chemical biology and industrial biotechnology). In addition, he works with UK Research Councils and consults with pharmaceutical and technology companies around the world.

Stevan Djuric

Vice President, Discovery Chemistry and Technology, AbbVie
Stevan Djuric

Dr Stevan Djuric is head of the global AbbVie Medicinal Chemistry Leadership Team at Abbott and is also responsible for the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities. The group’s current efforts are focused on new initiatives in the areas of high throughput synthesis and purification, hit to lead chemistry, chemical biology including target identification proteomics and new enabling technology identification and development.

He was named an AbbVie Distinguished Research Fellow in 2015

During his tenure at Abbott Laboratories, Dr Djuric has been a Project Leader for groups in the Immunoscience, Metabolic Disease, and Antiinfective areas. Several of these programs have advanced compounds into clinical development and to the market including Abbott’s proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe.

Dr Djuric has over 180 scientific publications, presentations and patents/applications pending. He has also given over 30 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards including the Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters and, in addition, holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas.
 

Steve Rees

Vice President Discovery Biology, Astra Zeneca
Steve Rees

Stephen Rees

VP Discovery Biology, Discovery Sciences, AstraZeneca, Milton Science Park, Cambridge, UK

In March 2017 Steve was appointed as Vice-President of the Discovery Biology department at AstraZeneca with global accountability for protein and cellular reagent generation and assay development, functional genomics and chemical biology. Prior to this Steve led the Screening Sciences and Sample Management department and successfully implemented strategies for hit identification, compound profiling, sample management and open innovation. Steve has led multiple international collaborations and has authored >60 scientific papers. Steve is currently Chair of the European Laboratory Research and Innovation group (ELRIG), has served as Chair of the SLAS Europe Council, is a member of the Scientific Advisory Board for Axol Biosciences, LifeArc and the Centre for Membrane Protein and Receptor research at the Universities of Nottingham and Birmingham.

Susanne Muller-Knapp

Senior Project Manager Chemical Probes, SGC Frankfurt, Goethe University Frankfurt
Susanne Muller-Knapp

Susanne Müller-Knapp studied Human Biology in Marburg Germany followed by a PhD in molecular biology at the Karolinska Institute in Stockholm, Sweden (1997). She then had more than 6 years of postdoctoral training in the area of inflammation and gene regulation at the Karolinska Institute and at the DIBIT San Raffaele Scientific Institute in Milan, Italy.
 

In 2004 Susanne joined the Structural Genomics Consortium, SGC, in Oxford. The SGC is an international public private partnership that currently comprises 9 international pharmaceutical companies and a large network of academic and industrial collaborators. Susanne worked at the SGC first as External Research Manager and then Scientific Coordinator. She has been the Project Manager of the Epigenetic Probe Project, which generates tool compounds with defined specificity and selectivity for epigenetic targets and the cell based assay group at the SGC in Oxford testing the cellular activity of the in vitro characterised tool compounds. In her role as Senior project manager for chemical probes at the SGC Frankfurt Susanne is now coordinating several probe programs including the global SGC kinase chemical probe program and a program of probes donated by SGC partners.

Ursula Egner

Director, Head of Structural Biology, Bayer AG
Ursula Egner

Ursula Egner is the director of Structural Biology at Bayer AG, Berlin. She studied physics and obtained her PhD in protein crystallography at the University of Heidelberg and University of Freiburg. In a postdoctoral position in the protein crystallography group of Wolfram Saenger at the Free University of Berlin she expanded her knowledge of structural biology in modeling of protein-ligand complexes with a primary focus on herbicide binding proteins. In the early 1990s, she joined Schering AG, now Bayer AG, to build up a homology modeling platform for protein-ligand complexes and pursuing the establishment of a platform linking structural biology information to bioinformatics data. Since 2000, she is Director of Structural Biology. Ursula’s main research interest is to facilitate early small molecule drug discovery by druggability assessments of targets, X-ray crystallography and fragment screening for hit identification. Her group strongly contributes to lead generation and optimization in the therapeutic areas of oncology and cardiology.

William Janzen

Executive Director, Lead Discovery, Epizyme
William Janzen

William P. Janzen is the Executive Director of Lead Discovery at Epizyme, Inc. Mr. Janzen has over twenty five years of experience in innovative drug discovery and has been a leader in the field of lead generation in academia, start-up companies and large pharmaceutical ventures. He has held executive and operational positions including President and Chief Operating Officer of Amphora Discovery, Director of Lead Generation Technologies at Eli Lilly and Company and Director of Assay Development and Compound Profiling at the University of North Carolina. Mr. Janzen was a founder of the Society for Biomolecular Screening (SBS) and served as president from 1998 – 2000. He was also on the board of directors of the SBS and Society for Laboratory Automation and Screening. He assembled the definitive work on high throughput screening, High Throughput Screening Methods and Protocols and has subsequently edited second and third editions of the book. Mr. Janzen has worked on over 500 drug discover projects in his career including numerous projects that have entered clinical trials.

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Darren Green, Director of Molecular Design, GSK

clock

9:10

KEYNOTE ADDRESS: Progress towards a contemporary medicinal chemistry technology toolkit

Stevan Djuric, Vice President, Discovery Chemistry and Technology, AbbVie

• Reducing cycle times and costs whilst improving the probability of technical success in the Drug Discovery process
• Advances in the development and introduction of several new enabling chemistry technologies, including flow photochemistry
• Integrating synthesis, purification and bioassay platforms
• Developing heterocycle synthesis by using a high temperature chemistry flow reactor

clock

9:50

SMN2 splicing modifiers for the treatment of spinal muscular atrophy. A journey 'from bench to bed’

Hasane Ratni, Expert Scientist, F. Hoffmann-La Roche Ltd.

• Discovery of the first tool molecules
• Optimization of their profile, potency, safety and pharmacodynamics
• Discovery of the clinical candidate
• Discussion of the unique mode of action of a small molecule interaction with mRNA
• Presentation of some clinical data

clock

10:30

Morning Coffee

clock

11:00

Open access chemical probes

Susanne Muller-Knapp, Senior Project Manager Chemical Probes, SGC Frankfurt, Goethe University Frankfurt

• Chemical probes: essential tools in biology and target validation- the Epigenetic example
• Living a public-private partnership: the SGC tool box
• Boosting open access research: The Donated Chemical Probes program

clock

11:40

High-quality chemical probes and drug discovery: a pharmaceutical industry perspective

Ursula Egner, Director, Head of Structural Biology, Bayer AG

• The Bayer – SGC collaboration: Advancing drug discovery by open innovation
• Know your target: Chemical probes trigger a better preclinical understanding of target candidates
• The seeding effect of chemical probes: Discovery of new biology with Bayer’s SMYD2 probe BAY-598

clock

12:20

Networking Lunch

clock

13:20

Enabling Drug Discovery for Challenging Targets

Roderick Hubbard, Professor & Senior Fellow, University of York & Vernalis Research

• Establishing feasibility – solving problems in protein production and assays
• Generating structural insight when x-ray crystallography is tough
• Illustrated with recent work on Mcl-1 and Bcl-2 (both now in Phase I trials)

clock

14:00

Strategies to inhibit the intracellular target Ras with potent antibody mimetic proteins

Ralph Minter, Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune

• Ras mutations are strong oncogenic drivers of many cancers but the target Ras is still not addressed by current therapies
• Using protein-based drugs to inhibit Ras is a novel approach
• We describe antibody mimetic proteins which block Ras by locking it in an inactive conformation
• These Ras inhibitory proteins enable us to explore the delivery of protein drugs into cells and study the biological implications of Ras inhibition

clock

14:40

Artificially intelligent drug design

Gisbert Schneider, Professor, Chair for Computer-Assisted Drug Design, ETH Zürich

• De novo compound design in silico
• Target prediction and off-target profiling
• Automating drug discovery by machine learning

clock

15:20

Afternoon Tea

clock

15:50

Transforming small molecule drug discovery using artificial intelligence

Andrew Hopkins, Professor & Chief Executive Officer, University of Dundee & Exscientia

• Exscientia’s automated design process mimics human creativity by designing molecules which integrate the wealth of available data
• Discover how Exscientia’s AI is delivering pre-clinical candidates with exception productivity
• Learn how artificial intelligence and human expertise can be best combined to re-design the drug discovery process
• The potential of AI to increase the capital efficacy of R&D

clock

16:30

Disrupting drug discovery with AI

Mark Davies, Vice President, Biomedical Informatics, BenevolentAI

• Highlighting the data challenges faced by the Drug Discovery industry
• Describing how AI can offer solutions to these problems by augmenting the Drug Discovery process
• Providing an overview of the AI focused workflows and tools developed by BenevolentAI
• Demonstrating the success of BenevolentAI approaches with specific examples

clock

17:10

Machine learning for smarter drug discovery

Claus Bendtsen, Executive Director & Head of Quantitative Biology, AstraZeneca

• Advances in machine learning is now having a real impact on how drug discovery is done.
• Increase efficiency in early R&D through a deeper understanding of the quality of our predictions, together with the ability to integrate diverse sources of information to form accurate predictions.
• Learn how to make better decision on which experiments to perform
• Reduce costs by learning from our historical data
• Discover new biology through analytics

clock

17:50

Chairman’s Closing Remarks and Close of Day One

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Guido Hanauer

Guido Hanauer, Chief Executive Officer, GHPC GmbH

clock

9:10

KEYNOTE ADDRESS: Drug discovery: transforming success through innovation and collaboration

Steve Rees, Vice President Discovery Biology, Astra Zeneca

• Application of the AstraZeneca 5R strategy for target selection
• Development of innovative capabilities for compound management and hit identification
• Transforming lead optimisation through the automation and miniaturisation of chemistry
• Developing a portfolio of diverse therapeutic modalities to enable any target to be prosecuted
• Innovative models of collaboration with pharma, vendor and academic partners

clock

9:50

Validating and invalidating targets, is CRISPR enough?

William Janzen, Executive Director, Lead Discovery, Epizyme

• The literature is full of misleading target validation references
• While a drug on the market is the ultimate validation of a target, there are biological and chemical steps along the way that lend credence to validation
• This talk will review and compare biological and chemical validation of targets

clock

10:30

Morning Coffee

clock

11:00

Applying multi-organ-on-a-chip technologies for predictive substance testing

Reyk Horland, Vice President, Business Development, TissUse GmbH

• Overview of the organ-on-a-chip landscape
• Introduction to Multi-Organ-on-a-chip solutions
• Case studies of industrial adoption of (Multi)-Organ-on-a-chip models
• Roadmap towards regulatory validation

clock

11:40

Drug Discovery in 3-Dimensions: A novel micro-scaffold-based approach for screening purposes – advantages and pitfalls

Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience

• We have developed a novel electrospun micro-scaffold based technology on to which we seed and grow recombinant cells, primary cell and differentiated stem cells
• These micro-scaffolds are magnetic, allowing each cell population to be manipulated in both culture tubes and assay plates. We have therefore use this approach to screen compounds in well plate based assays
• We will show data demonstrating the importance of 3-dimensional biology on micro-scaffolds used to generate a more physiological approach to testing compounds

clock

12:20

Networking Lunch

clock

13:20

Encoded library technologies in drug discovery

Christoph Dumelin, Laboratory Head, Novartis Institutes for BioMedical Research (NIBR), Novartis

• Overview of small and mid-size encoded library platforms at Novartis
• Application of encoded library technologies to drug discovery projects
• Discussion of 1-2 case studies

clock

14:00

Innovative modalities and business in the lead generation strategy

Patrick Jimonet, Director, External Innovation Drug Discovery, Sanofi

• Limitation of current Hit finding strategies in a rapidly changing drug discovery environment
• Cyclic peptides, macrocycles: new modalities to drug challenging targets
• Examples of innovative business models, partnerships and crowdsourcing to enhance Lead Generation efficiency
 

clock

14:40

Small-molecule induced protein degradation with PROTACs

John Harling

John Harling, Director of Chemistry for the Protein Degradation DPU, GSK

  • Small-molecule induced protein degradation represents an exciting new modality in drug discovery
  • This presentation will explain the basic science underlying this technology and how it offers unique opportunities for new medicines
  • Challenges in developing molecules with developable properties will be discussed
  • The scope of this technology will also be illustrated in terms of degradable targets and options for different E3 ligases
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    Antibody-enabled small molecule drug discovery

    Alastair Lawson, Head of Structural Biology and Research Fellow, UCB

    • Antibodies have successfully addressed modulation of protein-protein interactions in the clinic, and can enable the discovery of small molecules, which modulate biology in similar ways.
    • Antibodies have already proved to be of significant value as chaperones in structural studies, and are being used to stabilise proteins in specific conformations, providing new and previously unexpected opportunities for intervention with small molecules.
    • Small molecule fragment screening against antibody-constrained targets offers the prospect of discovering new chemical entities, which would otherwise be unable to gain a foothold on proteins.  The approach is particularly well suited to the discovery of small molecules which modulate protein-protein interactions through binding at allosteric sites.
     

    clock

    16:30

    Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery

    Nicholas Clare, Technical Project Leader, Axol Bioscience Ltd

  • The discovery and impact iPSCs
  • How can iPSCs revolutionise drug discovery?
  • The future of iPSCs
  • clock

    17:00

    Precise Genome Editing: CRISPR technologies in drug discovery

    Benjamin Taylor

    Benjamin Taylor, Associate Principal Scientist, AstraZeneca

  • Generating CRISPR models of disease
  • Prediction of drug resistance using CRISPR technology
  • Rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease
  • clock

    17:20

    Chairman’s Closing Remarks and Close of Day Two


    Head of Structural Biology and Research Fellow
    UCB
    Professor & Chief Executive Officer
    University of Dundee & Exscientia
    Associate Principal Scientist
    AstraZeneca
    Laboratory Head, Novartis Institutes for BioMedical Research (NIBR)
    Novartis
    Investigator III
    Novartis Pharmaceuticals
    Executive Director & Head of Quantitative Biology
    AstraZeneca
    Director of Molecular Design
    GSK
    Business Development Director and Chief Scientific Officer
    Aurelia Bioscience
    Professor, Chair for Computer-Assisted Drug Design
    ETH Zürich
    Chief Executive Officer
    GHPC GmbH
    Expert Scientist
    F. Hoffmann-La Roche Ltd.
    Director of Chemistry for the Protein Degradation DPU
    GSK
    Vice President, Biomedical Informatics
    BenevolentAI
    Technical Project Leader
    Axol Bioscience Ltd
    Director, External Innovation Drug Discovery
    Sanofi
    Director, Fellow, Antibody Discovery and Protein Engineering
    MedImmune
    Vice President, Business Development
    TissUse GmbH
    Professor & Senior Fellow
    University of York & Vernalis Research
    Vice President, Discovery Chemistry and Technology
    AbbVie
    Vice President Discovery Biology
    Astra Zeneca
    Senior Project Manager Chemical Probes
    SGC Frankfurt, Goethe University Frankfurt
    Director, Head of Structural Biology
    Bayer AG
    Executive Director, Lead Discovery
    Epizyme

    Sponsors and Exhibitors

    Supporters

    PRELIMINARY ATTENDEE LIST 2018

    Download

    CHAIRMANS LETTER

    Download

    PAST PRESENTATION- Guido Hanauer

    Download

    INTERVIEW WITH STEVAN DJURIC, ABBVIE

    Download

    INTERVIEW WITH REYK HORLAND, TISSUSE

    Download

    Snapshot of 2017 attendees

    Download

    Sponsors and Exhibitors


    Promega

    Sponsors and Exhibitors
    http://www.promega.co.uk

    Promega is a global leader in providing innovative solutions and technical support to life scientists asking fundamental questions about biological processes and applying scientific knowledge to discover new therapeutics, diagnose/treat diseases and use genetics for human identification.

    Media Partners


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    RareBase

    Supporters
    http://www.rarebase.co.uk

    The RareBase Networking Portal links people and companies throughout the world with an interest in rare and paediatric diseases.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Scidoc

    Supporters
    http://http://scidoc.org/index.php

    SciDoc is an Open Access publisher, aimed to facilitate the dissemination of research articles to the global community. SciDoc Publishers is established with a sole motive to disseminate knowledge among the scientific community. We as an Open Access publisher are on our way to be the world class leader in the provision of STM (Science, Technology and Medicine) Open Access content. This publishing model allows us to reach millions of readers and give them access to scientific publications- online, free of charge.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.